Oxidative damage impact on aging and age-related diseases: Drug targeting of telomere attrition and dynamic telomerase activity flirting with imidazole-containing dipeptides

Recent Patents on Drug Delivery and Formulation

Volumn 8, Issue 3, 2014, Pages 163-192

  Babizhayev, Mark A ^a,b   Vishnyakova, Khava S ^c   Yegorov, Yegor E ^c  

^a Innovative Vision Products Incorporated   (United States)

^b MOSCOW HELMHOLTZ RESEARCH INSTITUTE OF EYE DISEASES   (Russian Federation)

^c ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

Author keywords

Age related diseases; Carcinine; Cumulative oxidative stress; Healthy aging; Life expectancy; N acetylcarnosine; Natural imidazolecontaining peptidomimetics; Non hydrolyzed carnosine; Nutritional support; Telomere length protection; Telomeres and telomerase biology

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; CARCININE; CARNOSINE; DIPEPTIDE; DNA POLYMERASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; REACTIVE OXYGEN METABOLITE; TELOMERASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; ENZYME INHIBITOR; IMIDAZOLE; IMIDAZOLE DERIVATIVE;

AGING; ARTICLE; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; GLAUCOMA; HUMAN; LIFE EXPECTANCY; MULTIINFARCT DEMENTIA; OBESITY; OSTEOPOROSIS; OXIDATIVE STRESS; PHYSICAL DISEASE BY DEVELOPMENTAL AGE; PRIORITY JOURNAL; PULSE PRESSURE; REAL TIME POLYMERASE CHAIN REACTION; SENESCENCE; SENILE CATARACT; SMOKING; TELOMERE; TELOMERE SHORTENING; TISSUE INJURY; WRINKLE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENZYME ACTIVATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TELOMERE HOMEOSTASIS;

AGING; ANIMALS; CARNOSINE; DIPEPTIDES; DRUG DELIVERY SYSTEMS; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; OXIDATIVE STRESS; TELOMERASE; TELOMERE; TELOMERE HOMEOSTASIS;

EID: 84923559790     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872211308666140602125505     Document Type: Article

References (219)

1. Epel ES, Merkin SS, Cawthon R, Blackburn EH, Adler NE, Pletcher MJ, et al. The rate of leukocyte telomere shortening predicts mortality from cardiovascular disease in elderly men. Aging 2008; 1(1): 81-8.
2. Population reference bureau. Today Res Aging 2007; 1: 1-3.
3. Blackburn EH. Telomeres and telomerase: Their mechanisms of action and the effects of altering their functions. FEBS Lett 2005; 579(4): 859-62.
4. Kappei D, Londoño-Vallejo JA. Telomere length inheritance and aging. Mech Aging Dev 2008; 129(1-2): 17-26.
5. Njajou OT, Hsueh WC, Blackburn EH, Newman AB, Wu SH, Li R, et al. Health ABC study. Association between telomere length, specific causes of death, and years of healthy life in health, aging, and body composition, a population-based cohort study. J Gerontol A Biol Sci Med Sci 2009; 64(8): 860-4.
6. Wright WE, Shay JW. Telomere biology in aging and cancer. J Am Geriatr Soc 2005; 53(9): 292-4.
7. Babizhayev MA, Yegorov YE. Telomere attrition in lens epithelial cells-a target for N-acetylcarnosine therapy. Front Biosci 2010; 15: 934-56.
8. Babizhayev MA, Vishnyakova KS, Yegorov YE. Telomeredependent senescent phenotype of lens epithelial cells as a biological marker of aging and cataractogenesis: The role of oxidative stress intensity and specific mechanism of phospholipid hydroperoxide toxicity in lens and aqueous. Fundam Clin Pharmacol 2011; 25(2): 139-62.
9. Babizhayev MA, Savel’yeva EL, Moskvina SN, Yegorov YE. Telomere length is a biomarker of cumulative oxidative stress, biologic age, and an independent predictor of survival and therapeutic treatment requirement associated with smoking behavior. Am J Ther 2011; 18(6): e209-26.
10. Babizhayev MA, Yegorov YE. Smoking and health: Association between telomere length and factors impacting on human disease, quality of life and life span in a large population-based cohort under the effect of smoking duration. Fundam Clin Pharmacol 2011; 25(4): 425-42.
11. Kirkwood TB. Time of our lives. What controls the length of life? EMBO Rep 2005; 6: S4-8.
12. Finch CE. Longevity, senescence, and the genome. Chicago, IL, USA: Chicago University Press (1990).
13. Zubenko GS, Zubenko WN, Maher BS, Wolf NS. Reduced agerelated cataracts among elderly persons who reach age 90 with preserved cognition: A biomarker of successful aging? J Gerontol A Biol Sci Med Sci 2007; 62(5): 500-6.
14. Mitteldorf J. Aging is not a process of wear and tear. Rejuvenation Res 2010; 13(2-3): 322-6.
15. Kirkwood TB, Boys RJ, Gillespie CS, Proctor CJ, Shanley DP, Wilkinson DJ. Towards an e-biology of aging: Integrating theory and data. Nat Rev Mol Cell Biol 2003; 4(3): 243-9.
16. Franceschi C, Valensin S, Bonafè M, Paolisso G, Yashin AI, Monti D, et al. The network and the remodeling theories of aging: Historical background and new perspectives. Exp Gerontol 2000; 35(6-7): 879-96.
17. Yashin AI, De Benedictis G, Vaupel JW, Tan Q, Andreev KF, Iachine IA, et al. Genes and longevity: Lessons from studies of centenarians. J Gerontol A Biol Sci Med Sci 2000; 55(7): B319-28.
18. Bahar R, Hartmann CH, Rodriguez KA, Denny AD, Busuttil RA, Dollé ME, et al. Increased cell-to-cell variation in gene expression in aging mouse heart. Nature 2006; 441(7096): 1011-4.
19. Stadtman ER. Protein oxidation in aging and age-related diseases. Ann N Y Acad Sci 2001; 928: 22-38.
20. Levine RL. Carbonyl modified proteins in cellular regulation, aging, and disease. Free Radic Biol Med 2002; 32(9): 790-6.
21. Komatsu F, Kagawa Y, Kawabata T, Kaneko Y, Chimedregzen U, Purvee B, et al. A high accumulation of hair minerals in Mongolian people: 2(nd) report; influence of manganese, iron, lead, cadmium and aluminum to oxidative stress, Parkinsonism and arthritis. Curr Aging Sci 2011; 4(1): 42-56.
22. Komatsu F, Kagawa Y, Ishiguro K, Kawabata T, Purvee B, Otgon J, et al. The association of very high hair manganese accumulation and high oxidative stress in Mongolian people. Curr Aging Sci 2009; 2(1): 28-42.
23. Komatsu F, Kagawa Y, Kawabata T, Kaneko Y, Ishiguro K. Relationship of dietary habits and obesity to oxidative stress in Palauan people: Compared with Japanese and Mongolian people. Curr Aging Sci 2009; 2(3): 214-22.
24. Aoi W, Sakuma K. Oxidative stress and skeletal muscle dysfunction with aging. Curr Aging Sci 2011; 4(2): 101-9.
25. Østhus IB, Sgura A, Berardinelli F, Alsnes IV, Brønstad E, Rehn T, et al. Telomere length and long-term endurance exercise: Does exercise training affect biological age? A pilot study. PLoS One 2012; 7(12): e52769.
26. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical activity and public health: Updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 2007; 116(9): 1081-93.
27. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: A meta-analysis. JAMA 2009; 301(19): 2024-35.
28. Werner C, Fürster T, Widmann T, Pöss J, Roggia C, Hanhoun M, et al. Physical exercise prevents cellular senescence in circulating leukocytes and in the vessel wall. Circulation 2009; 120(24): 2438-47.
29. Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, et al. Physical activity and public health in older adults: Recommendation from the American College of Sports Medicine and the American Heart Association. Circulation 2007; 116(9): 1094-105.
30. Du M, Prescott J, Kraft P, Han J, Giovannucci E, Hankinson SE, et al. Physical activity, sedentary behavior, and leukocyte telomere length in women. Am J Epidemiol 2012; 175(5): 414-22.
31. LaRocca TJ, Seals DR, Pierce GL. Leukocyte telomere length is preserved with aging in endurance exercise-trained adults and related to maximal aerobic capacity. Mech Aging Dev 2010; 131(2): 165-7.
32. Woo J, Tang N, Leung J. No association between physical activity and telomere length in an elderly Chinese population 65 years and older. Arch Intern Med 2008; 168(19): 2163-4.
33. Shin YA, Lee JH, Song W, Jun TW. Exercise training improves the antioxidant enzyme activity with no changes of telomere length. Mech Aging Dev 2008; 129(5): 254-60.
34. Baguet A, Everaert I, Yard B, Peters V, Zschocke J, Zutinic A, et al. Does low serum carnosinase activity favour high-intensity exercise capacity? J Appl Physiol (1985) 2014; 116(5): 553-9.
35. Babizhayev, M.A., Meguro, K. Combined use of carnosinase inhibitor with L-carnosines and composition. WO2004064866 (2004).
36. Stegen S, Bex T, Vervaet C, Vanhee L, Achten E, Derave W. The beta-alanine dose for maintaining moderately elevated muscle carnosine levels. Med Sci Sports Exerc 2014; 46(7): 1426-32.
37. Balducci L. Treatment of cancer in the older aged person. Mediterr J Hematol Infect Dis 2010; 2(2): e2010029.
38. Prasad KN, Bondy SC. Evaluation of role of oxidative stress on aging in Caenorhabditis elegans: A brief review. Curr Aging Sci 2013; 6(3): 215-9.
39. Finch CE, Kirkwood TBL. Chance, development and aging. New York (2000); Oxford University Press: 278 pp.
40. Herndon LA, Schmeissner PJ, Dudaronek JM, Brown PA, Listner KM, Sakano Y, et al. Stochastic and genetic factors influence tissue-specific decline in aging C. elegans. Nature 2002; 419(6909): 808-14.
41. Rea SL, Wu D, Cypser JR, Vaupel JW, Johnson TE. A stresssensitive reporter predicts longevity in isogenic populations of Caenorhabditis elegans. Nat Genet 2005; 37(8): 894-8.
42. Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol 2003; 23(5): 842-6. Comment in: Arterioscler Thromb Vasc Biol 2003; 23(9): 1704.
43. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005; 366(9486): 662-4.
44. Frenck RW Jr, Blackburn EH, Shannon KM. The rate of telomere sequence loss in human leukocytes varies with age. Proc Natl Acad Sci USA 1998; 95(10): 5607-10.
45. Benetti R, García-Cao M, Blasco MA. Telomere length regulates the epigenetic status of mammalian telomeres and subtelomeres. Nat Genet 2007; 39(2): 243-50.
46. Celli GB, de Lange T. DNA processing is not required for ATMmediated telomere damage response after TRF2 deletion. Nat Cell Biol 2005; 7(7): 712-8.
47. Muñoz P, Blanco R, Flores JM, Blasco MA. XPF nucleasedependent telomere loss and increased DNA damage in mice overexpressing TRF2 result in premature aging and cancer. Nat Genet 2005; 37(10): 1063-71.
48. Steinert S, Shay JW, Wright WE. Modification of subtelomeric DNA. Mol Cell Biol 2004; 24(10): 4571-80.
49. Adams J, Martin-Ruiz C, Pearce MS, White M, Parker L, von Zglinicki T. No association between socio-economic status and white blood cell telomere length. Aging Cell 2007; 6(1): 125-8.
50. Cherkas LF, Hunkin JL, Kato BS, Richards JB, Gardner JP, Surdulescu GL, et al. The association between physical activity in leisure time and leukocyte telomere length. Arch Intern Med 2008; 168(2): 154-8.
51. Nordfjäll K, Eliasson M, Stegmayr B, Melander O, Nilsson P, Roos G. Telomere length is associated with obesity parameters but with a gender difference. Obesity 2008; 16(12): 2682-9.
52. Nordfjäll K, Eliasson M, Stegmayr B, Lundin S, Roos G, Nilsson PM. Increased abdominal obesity, adverse psychosocial factors and shorter telomere length in subjects reporting early aging; the MONICA Northern Sweden Study. Scand J Public Health 2008; 36(7): 744-52.
53. Nawrot TS, Staessen JA, Gardner JP, Aviv A. Telomere length and possible link to X chromosome. Lancet 2004; 363(9408): 507-10.
54. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr, Levrero M, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399(6738): 806-9.
55. Stiewe T, Pützer BM. p73 in apoptosis. Apoptosis 2001; 6(6): 447-52.
56. Wong JY, De Vivo I, Lin X, Fang SC, Christiani DC. The relationship between inflammatory biomarkers and telomere length in an occupational prospective cohort study. PLoS One 2014; 9(1): e87348.
57. Choi K, Kim J, Kim GW, Choi C. Oxidative stress-induced necrotic cell death via mitochondira-dependent burst of reactive oxygen species. Curr Neurovasc Res 2009; 6(4): 213-22.
58. Sohal RS, Dubey A. Mitochondrial oxidative damage, hydrogen peroxide release, and aging. Free Radic Biol Med 1994; 16(5): 621-6.
59. Cadenas E. Mitochondrial free radical production and cell signaling. Mol Aspects Med 2004; 25(1-2): 17-26.
60. Park KW, Baik HH, Jin BK. Interleukin-4-induced oxidative stress via microglial NADPH oxidase contributes to the death of hippocampal neurons in vivo. Curr Aging Sci 2008; 1(3): 192-201.
61. Zole E, Pliss L, Ranka R, Krumina A, Baumanis V. Dynamics of telomere length in different age groups in a Latvian population. Curr Aging Sci 2013; 6(3): 244-50.
62. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci USA 2004; 101(49): 17312-5. Comment in: Proc Natl Acad Sci USA 2004; 101(50): 17323-4; Int J Palliat Nurs 2009; 15(2): 55.
63. Harley CB, Futcher AB, Greider CW. Telomeres shorten during aging of human fibroblasts. Nature 1990; 345(6274): 458-60.
64. Blackburn EH. Telomeres. Trends Biochem Sci 1991; 16(10): 378-81.
65. Blackburn EH. Structure and function of telomeres. Nature 1991; 350(6319): 569-73.
66. Murga M, Jaco I, Fan Y, Soria R, Martinez-Pastor B, Cuadrado M, et al. Global chromatin compaction limits the strength of the DNA damage response. J Cell Biol 2007; 178(7): 1101-8.
67. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci 2002; 27(7): 339-44.
68. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426(6963): 194-8.
69. Passos JF, Saretzki G, Ahmed S, Nelson G, Richter T, Peters H, et al. Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol 2007; 5(5): e110.
70. Blackburn EH, Chan S, Chang J, Fulton TB, Krauskopf A, McEachern M, et al. Molecular manifestations and molecular determinants of telomere capping. Cold Spring Harb Symp Quant Biol 2000; 65: 253-63.
71. Petersen S, Saretzki G, von Zglinicki T. Preferential accumulation of single-stranded regions in telomeres of human fibroblasts. Exp Cell Res 1998; 239(1): 152-60.
72. Sitte N, Saretzki G, von Zglinicki T. Accelerated telomere shortening in fibroblasts after extended periods of confluency. Free Radic Biol Med 1998; 24(6): 885-93.
73. Counter CM. The roles of telomeres and telomerase in cell life span. Mutat Res 1996; 366(1): 45-63.
74. Rudolph KL, Chang S, Lee HW, Blasco M, Gottlieb GJ, Greider C, et al. Longevity, stress response, and cancer in aging telomerasedeficient mice. Cell 1999; 96(5): 701-12.
75. Harada H, Nakagawa H, Oyama K, Takaoka M, Andl CD, Jacobmeier B, et al. Telomerase induces immortalization of human esophageal keratinocytes without p16INK4a inactivation. Mol Cancer Res 2003; 1(10): 729-38.
76. Lindsey J, McGill NI, Lindsey LA, Green DK, Cooke HJ. In vivo loss of telomeric repeats with age in humans. Mutat Res 1991; 256(1): 45-8.
77. Blasco MA. Telomere length, stem cells and aging. Nat Chem Biol 2007; 3(10): 640-9.
78. Richter T, von Zglinicki T. A continuous correlation between oxidative stress and telomere shortening in fibroblasts. Exp Gerontol 2007; 42(11): 1039-42.
79. Greider CW. Telomere length regulation. Annu Rev Biochem 1996; 65: 337-65.
80. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA 1992; 89(21): 10114-8.
81. Jang JH, Bruse S, Huneidi S, Schrader RM, Monick MM, Lin Y, et al. Acrolein-Exposed normal human lung fibroblasts in vitro: Cellular senescence, enhanced telomere erosion, and degradation of Werner's syndrome protein. Environ Health Perspect 2014; 122(9): 955-62.
82. Jennings BJ, Ozanne SE, Dorling MW, Hales CN. Early growth determines longevity in male rats and may be related to telomere shortening in the kidney. FEBS Lett 1999; 448(1): 4-8.
83. Haussmann MF, Winkler DW, O'Reilly KM, Huntington CE, Nisbet IC, Vleck CM. Telomeres shorten more slowly in long-lived birds and mammals than in short-lived ones. Proc Biol Sci 2003; 270(1522): 1387-92.
84. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR. Protein composition of catalytically active human telomerase from immortal cells. Science 2007; 315(5820): 1850-3.
85. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003; 361(9355): 393-5. Comment in: Lancet 2003; 361(9364): 1224.
86. Starr JM, McGurn B, Harris SE, Whalley LJ, Deary IJ, Shiels PG. Association between telomere length and heart disease in a narrow age cohort of older people. Exp Gerontol 2007; 42(6): 571-3.
87. Joeng KS, Song EJ, Lee KJ, Lee J. Long lifespan in worms with long telomeric DNA. Nat Genet 2004; 36(6): 607-11.
88. Haussmann MF, Winkler DW, Vleck CM. Longer telomeres associated with higher survival in birds. Biol Lett 2005; 1(2): 212-4.
89. Herbig U, Ferreira M, Condel L, Carey D, Sedivy JM. Cellular senescence in aging primates. Science 2006; 311(5765): 1257.
90. Jemielity S, Kimura M, Parker KM, Parker JD, Cao X, Aviv A, et al. Short telomeres in short-lived males: What are the molecular and evolutionary causes? Aging Cell 2007; 6(2): 225-33.
91. Pauliny A, Wagner RH, Augustin J, Szép T, Blomqvist D. Ageindependent telomere length predicts fitness in two bird species. Mol Ecol 2006; 15(6): 1681-7.
92. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996; 18(2): 173-9.
93. Olovnikov AM. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol 1973; 41(1): 181-90.
94. Harley CB. Telomere loss: Mitotic clock or genetic time bomb? Mutat Res 1991; 2 56(2-6): 271-82.
95. Smeal T, Guarente L. Mechanisms of cellular senescence. Curr Opin Genet Dev 1997; 7(2): 281-7.
96. Johnson FB, Marciniak RA, Guarente L. Telomeres, the nucleolus and aging. Curr Opin Cell Biol 1998; 10(3): 332-8.
97. Harley CB, Sherwood SW. Telomerase, checkpoints and cancer. Cancer Surv 1997; 29: 263-84.
98. Kipling D. Telomeres, replicative senescence and human aging. Maturitas 2001; 38(1): 25-8.
99. Ostler EL, Wallis CV, Aboalchamat B, Faragher RG. Telomerase and the cellular lifespan: Implications of the aging process. J Pediatr Endocrinol Metab 2000; 13 Suppl 6: 1467-76.
100. Wright WE, Shay JW. The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol 1992; 27(4): 383-9.
101. de Lange T. Telomeres and senescence: Ending the debate. Science 1998; 279(5349): 334-5.
102. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM. Evidence for a mitotic clock in human hematopoietic stem cells: Loss of telomeric DNA with age. Proc Natl Acad Sci USA 1994; 91(21): 9857-60.
103. Salk D. Can we learn about aging from a study of Werner's syndrome? J Am Geriatr Soc 1982; 30(5): 334-9.
104. Dorman JB, Albinder B, Shroyer T, Kenyon C. The age-1 and daf-2 genes function in a common pathway to control the lifespan of Caenorhabditis elegans. Genetics 1995; 141(4): 1399-406.
105. Guarente L. Do changes in chromosomes cause aging? Cell 1996; 86(1): 9-12.
106. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996; 18(2): 173-9.
107. Hosokawa M. A higher oxidative status accelerates senescence and aggravates age-dependent disorders in SAMP strains of mice. Mech Aging Dev 2002; 123(12): 1553-61.
108. Fujisawa H, Nishikawa T, Zhu BH, Takeda N, Jujo H, Higuchi K, et al. Accelerated aging of dermal fibroblast-like cells from the senescence-accelerated mouse (SAM): Acceleration of changes in DNA ploidy associated with in vitro cellular aging. J Gerontol A Biol Sci Med Sci 1998; 53(1): B11-7.
109. Oshimura M, Barrett JC. Multiple pathways to cellular senescence: Role of telomerase repressors. Eur J Cancer 1997; 33(5): 710-5.
110. Holt SE, Wright WE, Shay JW. Multiple pathways for the regulation of telomerase activity. Eur J Cancer 1997; 33(5): 761-6.
111. Oshimura M, Shimizu M, Kugoh H. Genetic regulation of telomerase in a multiple pathways model to cellular senescence. Hum Cell 1996; 9(4): 301-8.
112. Norton JC, Piatyszek MA, Wright WE, Shay JW, Corey DR. Inhibition of human telomerase activity by peptide nucleic acids. Nat Biotechnol 1996; 14(5): 615-9.
113. Zeng Z, Wang W, Yang Y, Chen Y, Yang X, Diehl JA, et al. Structural basis of selective ubiquitination of TRF1 by SCFFbx4. Dev Cell 2010; 18(2): 214-25.
114. Wright WE, Brasiskyte D, Piatyszek MA, Shay JW. Experimental elongation of telomeres extends the lifespan of immortal x normal cell hybrids. EMBO J 1996; 15(7): 1734-41.
115. Watson JM, Riha K. Telomeres, aging, and plants: From weeds to methuselah-a mini-review. Gerontology 2011; 57(2): 129-36.
116. Watson JM, Shippen DE. Telomere rapid deletion regulates telomere length in Arabidopsis thaliana. Mol Cell Biol 2007; 27(5): 1706-15.
117. Weinstein BS, Ciszek D. The reserve-capacity hypothesis: Evolutionary origins and modern implications of the trade-off between tumor-suppression and tissue-repair. Exp Gerontol 2002; 37(5): 615-27.
118. Cooke HJ, Smith BA. Variability at the telomeres of the human X/Y pseudoautosomal region. Cold Spring Harb Symp Quant Biol 1986; 51(1): 213-9.
119. Harley CB. Human aging and telomeres. Ciba Found Symp 1997; 211: 129-44.
120. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with aging. Nature 1990; 346(6287): 866-8. Comment in: Nature 1991; 350(6315): 197.
121. Jackson SR, Lee J, Reddy R, Williams GN, Kikuchi A, Freiberg Y, et al. Partial pneumonectomy of telomerase null mice carrying shortened telomeres initiates cell growth arrest resulting in a limited compensatory growth response. Am J Physiol Lung Cell Mol Physiol 2011; 300(6): L898-909.
122. Pommier JP, Lebeau J, Ducray C, Sabatier L. Chromosomal instability and alteration of telomere repeat sequences. Biochimie 1995; 77(10): 817-25.
123. Aviv A. Telomeres and human aging: Facts and fibs. Sci Aging Knowledge Environ 2004; 2004(51): pe43.
124. Houben JM, Giltay EJ, Rius-Ottenheim N, Hageman GJ, Kromhout D. Telomere length and mortality in elderly men: The Zutphen Elderly Study. J Gerontol A Biol Sci Med Sci 2011; 66(1): 38-44.
125. Gardner JP, Li S, Srinivasan SR, Chen W, Kimura M, Lu X, Berenson GS, et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation 2005; 111(17): 2171-7.
126. Saretzki G, Von Zglinicki T. Replicative aging, telomeres, and oxidative stress. Ann N Y Acad Sci 2002; 959: 24-9.
127. Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West MD, et al. Telomerase, cell immortality, and cancer. Cold Spring Harb Symp Quant Biol 1994; 59: 307-15.
128. Newbold RF. Genetic control of telomerase and replicative senescence in human and rodent cells. Ciba Found Symp 1997; 211: 177-97.
129. Giardini MA, Segatto M, da Silva MS, Nunes VS, Cano MI. Telomere and telomerase biology. Prog Mol Biol Transl Sci 2014; 125: 1-40.
130. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci USA 1995; 92(24): 11190-4.
131. Kitada T, Seki S, Kawakita N, Kuroki T, Monna T. Telomere shortening in chronic liver diseases. Biochem Biophys Res Commun 1995; 211(1): 33-9.
132. Effros RB, Allsopp R, Chiu CP, Hausner MA, Hirji K, Wang L, et al. Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 1996; 10(8): F17-22.
133. Kurz DJ, Decary S, Hong Y, Trivier E, Akhmedov A, Erusalimsky JD. Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J Cell Sci 2004; 117(Pt 11): 2417-26.
134. Jeanclos E, Schork NJ, Kyvik KO, Kimura M, Skurnick JH, et al. Telomere length inversely correlates with pulse pressure and is highly familial. Hypertension 2000; 36(2): 195-200.
135. Gilson E, Londoño-Vallejo A. Telomere length profiles in humans: All ends are not equal. Cell Cycle 2007; 6(20): 2486-94.
136. Benetos A, Okuda K, Lajemi M, Kimura M, Thomas F, Skurnick J, et al. Telomere length as an indicator of biological aging: The gender effect and relation with pulse pressure and pulse wave velocity. Hypertension 2001; 37(2): 381-5.
137. Zannolli R, Mohn A, Buoni S, Pietrobelli A, Messina M, Chiarelli F, et al. Telomere length and obesity. Acta Paediatr 2008; 97(7): 952-4.
138. von Zglinicki T, Serra V, Lorenz M, Saretzki G, Lenzen-Grossimlighaus R, Gessner R, et al. Short telomeres in patients with vascular dementia: An indicator of low antioxidative capacity and a possible risk factor? Lab Invest 2000; 80(11): 1739-47.
139. Aviv A, Valdes A, Gardner JP, Swaminathan R, Kimura M, Spector TD. Menopause modifies the association of leukocyte telomere length with insulin resistance and inflammation. J Clin Endocrinol Metab 2006; 91(2): 635-40.
140. Sampson MJ, Winterbone MS, Hughes JC, Dozio N, Hughes DA. Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes. Diabetes Care 2006; 29(2): 283-9.
141. Adaikalakoteswari A, Balasubramanyam M, Mohan V. Telomere shortening occurs in Asian Indian Type 2 diabetic patients. Diabet Med 2005; 22(9): 1151-6.
142. Kuhlow D, Florian S, von Figura G, Weimer S, Schulz N, Petzke KJ, et al. Telomerase deficiency impairs glucose metabolism and insulin secretion. Aging 2010; 2(10): 650-8.
143. Samani NJ, Boultby R, Butler R, Thompson JR, Goodall AH. Telomere shortening in atherosclerosis. Lancet 2001; 358(9280): 472-3.
144. Brouilette SW, Whittaker A, Stevens SE, van der Harst P, Goodall AH, Samani NJ. Telomere length is shorter in healthy offspring of subjects with coronary artery disease: Support for the telomere hypothesis. Heart 2008; 94(4): 422-5.
145. Kurz DJ, Kloeckener-Gruissem B, Akhmedov A, Eberli FR, Bühler I, Berger W, et al. Degenerative aortic valve stenosis, but not coronary disease, is associated with shorter telomere length in the elderly. Arterioscler Thromb Vasc Biol 2006; 26(6): e114-7.
146. Savale L, Chaouat A, Bastuji-Garin S, Marcos E, Boyer L, Maitre B, et al. Shortened telomeres in circulating leukocytes of patientswith chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179(7): 566-71.
147. Valdes AM, Deary IJ, Gardner J, Kimura M, Lu X, Spector TD, et al. Leukocyte telomere length is associated with cognitive performance in healthy women. Neurobiol Aging 2010; 31(6): 986-92.
148. Fitzpatrick AL, Kronmal RA, Gardner JP, Psaty BM, Jenny NS, Tracy RP, et al. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiol 2007; 165(1): 14-21.
149. Huzen J, de Boer RA, van Veldhuisen DJ, van Gilst WH, van der Harst P. The emerging role of telomere biology in cardiovascular disease. Front Biosci 2010; 15: 35-45.
150. Oeseburg H, de Boer RA, van Gilst WH, van der Harst P. Telomere biology in healthy aging and disease. Pflugers Arch 2010; 459(2): 259-68.
151. Wang C, Maddick M, Miwa S, Jurk D, Czapiewski R, Saretzki G, et al. Adult-onset, short-term dietary restriction reduces cell senescence in mice. Aging 2010; 2(9): 555-66.
152. Demissie S, Levy D, Benjamin EJ, Cupples LA, Gardner JP, Herbert A, et al. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell 2006; 5(4): 325-30.
153. Bakaysa SL, Mucci LA, Slagboom PE, Boomsma DI, McClearn GE, Johansson B, et al. Telomere length predicts survival independent of genetic influences. Aging Cell 2007; 6(6): 769-74.
154. Kimura M, Hjelmborg JV, Gardner JP, Bathum L, Brimacombe M, Lu X, et al. Telomere length and mortality: A study of leukocytes in elderly Danish twins. Am J Epidemiol 2008; 167(7): 799-806.
155. Honig LS, Schupf N, Lee JH, Tang MX, Mayeux R. Shorter telomeres are associated with mortality in those with APOE epsilon4 and dementia. Ann Neurol 2006; 60(2): 181-7.
156. Martin-Ruiz C, Dickinson HO, Keys B, Rowan E, Kenny RA, Von Zglinicki T. Telomere length predicts poststroke mortality, dementia, and cognitive decline. Ann Neurol 2006; 60(2): 174-80.
157. Bischoff C, Petersen HC, Graakjaer J, Andersen-Ranberg K, Vaupel JW, Bohr VA, et al. No association between telomere length and survival among the elderly and oldest old. Epidemiology 2006; 17(2): 190-4.
158. Martin-Ruiz CM, Gussekloo J, van Heemst D, von Zglinicki T, Westendorp RG. Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: A populationbased study. Aging Cell 2005; 4(6): 287-90.
159. Serrano AL, Andrés V. Telomeres and cardiovascular disease: Does size matter? Circ Res 2004; 94(5): 575-84.
160. De Meyer T, Rietzschel ER, De Buyzere ML, Van Criekinge W, Bekaert S. Studying telomeres in a longitudinal population based study. Front Biosci 2008; 13: 2960-70.
161. Young RC, Kitaysky AS, Haussmann MF, Descamps S, Orben RA, Elliott KH, Gaston AJ. Age, sex, and telomere dynamics in a longlived seabird with male-biased parental care. PLoS One 2013; 8(9): e74931.
162. Ricklefs RE. Insights from comparative analyses of aging in birds and mammals. Aging Cell 2010; 9(2): 273-84.
163. Campisi J. The role of cellular senescence in skin aging. J Investig Dermatol Symp Proc 1998; 3(1): 1-5.
164. Effros RB. Telomerase induction in T cells: A cure for aging and disease? Exp Gerontol 2007; 42(5): 416-20.
165. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279(5349): 349-52.
166. Kim M, Xu L, Blackburn EH. Catalytically active human telomerase mutants with allele-specific biological properties. Exp Cell Res 2003; 288(2): 277-87.
167. Effros RB. Replicative senescence of CD8 T cells: Potential effects on cancer immune surveillance and immunotherapy. Cancer Immunol Immunother 2004; 53(10): 925-33.
168. Babizhayev MA, Deyev AI. Management of the virulent influenza virus infection by oral formulation of non-hydrolyzed carnosine and isopeptide of carnosine attenuating proinflammatory cytokineinduced nitric oxide production. Am J Ther 2012; 19(1): e25-47.
169. Boldyrev AA, Severin SE. The histidine-containing dipeptides, carnosine and anserine: Distribution, properties and biological significance. Adv Enzyme Regul 1990: 175-94.
170. Babizhayev MA, Yegorov YE. Therapeutic uses of drug-carrier systems for imidazole-containing dipeptide compounds that act as pharmacological chaperones and have significant impact on the treatment of chronic diseases associated with increased oxidative stress and the formation of advanced glycation end products. Crit Rev Ther Drug Carrier Syst 2010; 27(2): 85-154.
171. Lenney JF. Specificity and distribution of mammalian carnosinase. Biochim Biophys Acta 1976; 429(1): 214-9.
172. Jackson MC, Kucera CM, Lenney JF. Purification and properties of human serum carnosinase. Clin Chim Acta 1991; 196(2-3): 193-205.
173. Babizhayev MA, Yegorov YE. Advanced drug delivery of NAcetylcarnosine (N-Acetyl-beta-alanyl-L-histidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl-L-histidine) in targeting peptide compounds as pharmacological chaperones for use in tissue engineering, human disease management and therapy: From in vitro to the clinic. Recent Pat Drug Deliv Formul 2010; 4(3): 198-230.
174. Lenney JF. Separation and characterization of two carnosinesplitting cytosolic dipeptidases from hog kidney (carnosinase and non-specific dipeptidase). Biol Chem Hoppe Seyler 1990; 371(5): 433-40.
175. Kunze N, Kleinkauf H, Bauer K. Characterization of two carnosine-degrading enzymes from rat brain. Partial purification and characterization of a carnosinase and a beta-alanyl-arginine hydrolase. Eur J Biochem 1986; 160(3): 605-13.
176. Babizhayev MA, Yegorov YE. Biomarkers of oxidative stress and cataract. Novel drug delivery therapeutic strategies targeting telomere reduction and the expression of telomerase activity in the lens epithelial cells with n-acetylcarnosine lubricant eye drops: Anti-cataract which helps to prevent and treat cataracts in the eyes of dogs and other animals. Curr Drug Deliv 2014; 11(1): 24-61.
177. Aldini G, Facino RM, Beretta G, Carini M. Carnosine and related dipeptides as quenchers of reactive carbonyl species: From structural studies to therapeutic perspectives. Biofactors 2005; 24(1-4): 77-87.
178. Aldini G, Orioli M, Carini M, Maffei Facino R. Profiling histidinecontaining dipeptides in rat tissues by liquid chromatography/ electrospray ionization tandem mass spectrometry. J Mass Spectrom 2004; 39(12): 1417-28.
179. Reddy VP, Garrett MR, Perry G, Smith MA. Carnosine: A versatile antioxidant and antiglycating agent. Sci Aging Knowledge Environ 2005; 2005(18): 12.
180. Rashid I, van Reyk DM, Davies MJ. Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro. FEBS Lett 2007; 581(5): 1067-70.
181. Babizhayev MA. Antioxidant activity of L-carnosine, a natural histidine-containing dipeptide in crystalline lens. Biochim Biophys Acta 1989; 1004(3): 363-71.
182. Babizhayev MA, Micans P, Guiotto A, Kasus-Jacobi A. Nacetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: A clinical study of the new visionsaving drug N-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients. Am J Ther 2009; 16(6): 517-33.
183. Babizhayev MA. Current ocular drug delivery challenges for Nacetylcarnosine: Novel patented routes and modes of delivery, design for enhancement of therapeutic activity and drug delivery relationships. Rec Pat Drug Deliv Formul 2009; 3(3): 229-65.
184. Babizhayev MA, Kasus-Jacobi A. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases. Curr Clin Pharmacol 2009; 4(1): 4-37.
185. Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Kurysheva NI, et al. N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides 2001; 22: 979-94.
186. Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Kurysheva NI, et al. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs Res Develop 2002; 3(2): 87-103.
187. Babizhayev MA, Deyev AI, Yermakova VN, Remenschikov VV, Bours J. Revival of the lens transparency with N-acetylcarnosine. Curr Drug Ther 2006; 1: 91-116.
188. Babizhayev MA, Deyev AI, Yermakova VN, Brikman IV, Bours J. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs Res Develop 2004; 5(3): 125-39.
189. Babizhayev, M.A. Method for topical treatment of eye disease and composition and device for said treatment. WO2004028536A1 (2004).
190. Babizhayev MA. Ophthalmic pharmacology of N-acetylcarnosine lubricant eye drops. J Pharmacol Toxicol 2006; 1(3): 201-33.
191. Babizhayev MA. Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops. Rejuven Res 2004; 7: 186-98.
192. Babizhayev MA, Yermakova VN, Deyev AI, Seguin M-C. Imidazole-containing peptidomimetic NACA as a potent drug for the medicinal treatment of age-related cataract in humans. J Anti-Aging Med 2000; 3: 43-62.
193. Çoban J, Bingül I, Yesil-Mizrak K, Dogru-Abbasoglu S, Oztezcan S, Uysal M. Effects of carnosine plus vitamin E and betaine treatments on oxidative stress in some tissues of aged rats. Curr Aging Sci 2013; 6(2): 199-205.
194. de Oliveira BF, Veloso CA, Nogueira-Machado JA, Martins Chaves M. High doses of in vitro beta-carotene, alpha-tocopherol and ascorbic acid induce oxidative stress and secretion of IL-6 in peripheral blood mononuclear cells from healthy donors. Curr Aging Sci 2012; 5(2): 148-56.
195. Rybakova Y, Akkuratov E, Kulebyakin K, Brodskaya O, Dizhevskaya A, Boldyrev A. Receptor-mediated oxidative stress in murine cerebellar neurons is accompanied by phosphorylation of MAP (ERK 1/2) kinase. Curr Aging Sci 2012; 5(3): 225-30.
196. Arnould JM, Frentz R. Presence. Isolation and chemical structure of a substance characteristic of cardiac tissue in Carcinus maenas (L.): Beta-alanylhistamine. Comp Biochem Physiol C 1975; 50(1): 59-66.
197. Brotman DN, Flancbaum L, Fitzpatrick JC, Fisher H. Presence of carcinine (˜-alanylhistamine) in mammalian tissues. FASEB J 1989; 3: 1028.
198. Brotman DN, Flancbaum L, Kang YH, Merrill GF, Fisher, H. Positive inotropic effects of carcinine in the isolated, perfused guinea pig heart. Crit Care Med 1990; 18: 317-21.
199. Flancbaum L, Brotman DN, Fitzpatrick JC, Van Es T, Kasziba, E, Fisher H. Existence of carcinine, a histamine-related compound, in mammalian tissues. Life Sci 1990; 47: 1587-93.
200. Ali SM, Tedford CE, Gregory R, Handley MK, Yates SL, Hirth WW, et al. Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists. J Med Chem 1999; 42: 903-9.
201. Tedford CE, Phillips JG, Gregory R, Pawlowski GP, Fadnis L, Khan MA, et al. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands. J Pharmacol Exp Ther 1999; 289: 1160-8.
202. Yates SL, Phillips JG, Gregory R, Pawlowski GP, Fadnis L, Khan MA, et al. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands. J Pharmacol Exp Ther 1999; 289(2): 1151-9.
203. Tozer MJ, Kalindjian SB. Histamine H3 receptor antagonists. Expert Opin Ther 2000; 10: 1045-55.
204. Chen Z, Sakurai E, Hu W, Jin C, Kiso Y, Kato M, et al. Pharmacological effects of carcinine on histaminergic neurons in the brain. Br J Pharmacol 2004; 143(5): 573-80.
205. Babizhayev MA. Biological activities of the natural imidazolecontaining peptidomimetics n-acetylcarnosine, carcinine and Lcarnosine in ophthalmic and skin care products. Life Sci 2006; 78(20): 2343-57.
206. Babizhayev MA, Seguin MC, Gueyne J, Evstigneeva RP, Ageyeva EA, Zheltukhina GA. L-carnosine (beta-alanyl-L-histidine) and carcinine (beta-alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid-peroxidase activities. Biochem J 1994; 304(2): 509-16.
207. Arnould JM, Frentz R. Carcinine (b-alanyl-histamine): Rapid synthesis and action on vertebrate blood pressure. Arch Int Physiol Biochim 1977; 85(2): 339-50.
208. Babizhayev MA, Kasus-Jacobi A. Imidazole-containing peptidebased compounds in sight-threatening age-related eye diseases. Expert Rev Ophthalmol 2009; 4(6): 581-6.
209. Babizhayev MA. Designation of imidazole-containing dipeptides as pharmacological chaperones. Hum Exp Toxicol 2011; 30(7): 736-61.
210. Holliday R, McFarland GA. A role for carnosine in cellular maintenance. Biochemistry 2000; 65: 843-8.
211. McFarland GA, Holliday R. Retardation of the senescence of cultured human diploid fibroblasts by carnosine. Exp Cell Res 1994; 212: 167-75.
212. McFarland GA, Holliday R. Further evidence for the rejuvenating effects of the dipeptide L-carnosine on cultured human diploid fibroblasts. Exp Gerontol 1999; 34: 35-45.
213. Kurella EG, Mal'tseva VV, Seslavina LS, Stvolinskiĭ SL. Stimulating effects of carnosine on hemopoietic stem cells. Biull Eksp Biol Med 1991; 112(7): 52-3.
214. Shao L, Li QH, Tan Z. L-carnosine reduces telomere damage and shortening rate in cultured normal fibroblasts. Biochem Biophys Res Commun 2004; 324(2): 931-6.
215. Babizhayev MA. New concept in nutrition for the maintenance of the aging eye redox regulation and therapeutic treatment of cataract disease; synergism of natural antioxidant imidazole-containing amino acid-based compounds, chaperone, and glutathione boosting agents: A systemic perspective on aging and longevity emerged from studies in humans. Am J Ther 2010; 17(4): 373-89.
216. Fenton M, Barker S, Kurz DJ, Erusalimsky JD. Cellular senescence after single and repeated balloon catheter denudations of rabbit carotid arteries. Arterioscler Thromb Vasc Biol 2001; 21(2): 220-6.
217. Vasile E, Tomita Y, Brown LF, Kocher O, Dvorak HF. Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: Evidence for senescent endothelial cells in vivo at sites of atherosclerosis. FASEB J 2001; 15(2): 458-66.
218. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: Role of telomere in endothelial dysfunction. Circulation 2002; 105(13): 1541-4.
219. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation 1997; 96(10): 3264-5.